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Abstract
Objective: Individuals with Attention-Deficit/Hyperactivity Disorder (ADHD) are at increased 
risk of poor school performance and pharmacological treatment of ADHD may have beneficial 
effects on school performance. Conclusions from previous research have been limited by small 
sample sizes, outcome measures, and treatment follow-up. The current study analyzed school 
performance in students with ADHD compared to students without ADHD, and the association 
between pharmacological treatment of ADHD and school performance.
Method: A linkage of Swedish national registers covering 657,720 students graduating from year 
9 of compulsory school provided measures of school performance, electronically recorded 
dispensations of ADHD medication, and potentially confounding background factors such as 
parental socioeconomic status. Primary measures of school performance included student 
eligibility to upper secondary school and grade point sum.
Results: ADHD was associated with substantially lower school performance independent of 
socioeconomic background factors. Treatment with ADHD medication for 3 months was 
positively associated with all primary outcomes, including a decreased risk of no eligibility to 
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upper secondary school, odds ratio of 0.80, 95% confidence interval (CI) 0.76-0.84, and a higher 
grade point sum (range 0.0-320.0) of 9.35 points, 95% CI=7.88-10.82; standardized coefficient of 
0.20.
Conclusion: ADHD has a substantial negative impact on school performance while 
pharmacological treatment for ADHD is associated with higher levels in several measures of 
school performance. Our findings emphasize the importance of detection and treatment of ADHD 
at an early stage to reduce the negative impact on school performance.
LAY SUMMARY
Attention-Deficit/Hyperactivity Disorder (ADHD) is associated with poor school performance and 
ADHD medication may improve school performance. Using a register linkage of Swedish students 
this study finds a positive association between length of medication use prior to graduation and 
several measures of school performance. Three months of treatment with ADHD medication was 
associated with an increase in the grade-point average (range 0-20) of 0.49 and treatment over 
three school years with an increase of 2.38 points. The strength of these associations suggest that 
ADHD medication may play a role in improving school performance in students with ADHD, but 
other educational interventions are likely needed to bridge the substantial school performance gap 
between students affected by ADHD and their unaffected peers.
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INTRODUCTION
Approximately 5% of all school-aged children world-wide are diagnosed with Attention-
Deficit/Hyperactivity Disorder (ADHD)1 and the impairments associated with ADHD 
persist into adulthood in many cases.2 Research suggests that ADHD is associated with poor 
school performance, both in childhood and later in life. Children with ADHD are at 
increased risk of lower scores on reading and arithmetic achievement tests, lower grade point 
average (GPA), grade repetition and placement in special education classes compared to 
controls.3–5 Adolescents with ADHD fail more grades and perform worse on standardized 
academic achievement tests than matched controls.6 Although the relationship between 
ADHD and school performance is well-researched, no study has examined this relationship 
in a nationwide setting using objectively measured confounders such as parental education.
Randomized controlled trials (RCTs) involving children7 and adults8 have shown that 
ADHD medications have beneficial short-term effects on the core symptoms of ADHD and 
are associated with improvements in a wide range of cognitive functions in children with 
ADHD, including complex reaction time, spatial recognition memory reaction time, 
inhibition, working memory and strategy formation.9 Research on the short-term effects of 
ADHD medication on different measures of school performance has found positive effects in 
several domains. RCTs, usually with a follow-up of 1-7 weeks,10,11 suggest positive effects 
on note-taking quality, quiz scores, class work productivity, and disruptive behavior,12,13 
whereas more modest effects have been reported for test scores in reading and mathematics.
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7,14,15 Observational studies exploring short-term effects have found converging evidence.
16,17 One recent study using Swedish register data found that, although of small effect, 
individuals (mean age 22.2 years) performed better on higher education entrance tests during 
medicated than unmedicated periods16 and another study in children using a similar design 
found that GPA was higher during stimulant adherent periods.17
Ideally, the long-term association between ADHD medication and school performance 
should be examined in large prospective RCTs, but since such trials are problematic (e.g., 
patients assigned to a long-term untreated control arm may seek out medications elsewhere) 
and unethical (e.g., withholding treatment with known benefits), future research in this area 
must rely on findings from observational designs.
Existing observational studies of the long-term association between ADHD medication and 
school performance have yielded inconsistent results.18–21 Although improvements in test 
scores during primary school have been reported,22,23 the evidence regarding GPA is mixed. 
A 9-year longitudinal follow-up study of children with ADHD showed an association 
between ADHD medication and higher GPA21 and an 8-year follow-up of the Multimodal 
Treatment Study of Attention Deficit Hyperactivity Disorder (MTA) reported no effects of 
ADHD medication on GPA.20 Imperfect assessment (e.g., parent- or self-reported) of long-
term medication usage, and small and/or clinically referred samples are essential limitations 
of the available studies.18 Another important limitation of the aforementioned observational 
research is how different measures of school performance influence each other. Standardized 
tests can be conceptualized as examinations of academic knowledge while school grades, in 
addition, incorporate broader aspects of school performance such as productivity and 
classroom behavior.24 One review reported that the correlation between test scores and grade 
points is lower in students with ADHD compared to students without ADHD18, suggesting 
that teacher assessment differs by ADHD status. The potential role of ADHD medications in 
this relationship is unknown.
The current study captured the total population of students graduating from compulsory 
(primary and lower secondary) school in Sweden in 2008-2013, including a large sample of 
students diagnosed with ADHD. The aims were twofold: First, we investigated the 
association between ADHD and school performance. Second, we examined how ADHD 




We extracted data on school performance from the Swedish National School Register (NSR) 
for all 657,720 students graduating from year 9 of compulsory school between 2008 and 
2013. The NSR contains individual level data on final grades (FGs) from school leaving 
certificates and grades in standardized tests (subsequently referred to as tests) taken in 
Swedish, English and mathematics, information about eligibility to upper secondary school 
(USS), and school of graduation. Using the Longitudinal Integration Database for Health 
Insurance and Labor Market Studies (LISA) individual completion of USS was obtained. 
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Individuals were linked to data on dispensed medication, including amphetamine 
(Anatomical Therapeutic Chemical classification system (ATC) codes: N06BA01, 
N06BA02), methylphenidate (N06BA04) and atomoxetine (N06BA09), using the Swedish 
Prescribed Drug Register (July 2005 – December 2013) and diagnosis of ADHD 
(International Classification of Diseases [ICD] 10: F90), in the National Patient Register 
(NPR). ADHD cases were defined either by a lifetime in/outpatient primary diagnosis of 
ADHD or at least one lifetime dispensation of ADHD medication (excluding dispensations 
indicated for narcolepsy; 93 individuals). Defining ADHD by a dispensed ADHD 
medication has been used and validated in prior research using Swedish registers.25 This 
study was approved by the Regional Ethical Review Board in Stockholm. In Sweden, using 
de-identified register data in research does not require informed consent from participants.
The Swedish school system
The Swedish primary and lower secondary school is compulsory by law and 9 years in 
length where each scholastic year starts in mid-August and ends in early June. FGs received 
upon graduation in the 9th year determines the options available for a student to advance to 
USS. First, eligibility to any of the national programs in USS requires the student to pass all 
“core subjects” (Swedish, English and mathematics). Second, eligibility differs between 
vocational and higher education preparatory programs. In general, preparatory programs 
require a passing grade in an additional 9 subjects (passing certain subjects is necessary for 
some of these). Until 2011, vocational eligibility only required passing the core subjects 
while, 2011 and later, passing an additional 5 subjects was required (in total 8). If the 
number of applicants to a program exceeds the available slots, these are distributed to the 
highest achievers using a grade point sum, the merit value, constructed by scoring the 
alphabetical grade in each subject (0-20 points) and summing the student’s 16 best-
performing subjects (range 0-320).26 A schematic of the Swedish school system is presented 
in Figure 1.
In the spring semester of their final year 9, students also take three tests in each of the core 
subjects. Each student receives a weighted grade in each subject that reflects overall 
performance on the tests and teachers are supposed to take these results into account when 
setting FGs at the end of the scholastic year.
The national USS programs are 3 years in length. Ineligible students are admitted to one of 
the introductory programs that prepare the student for either the labor market or one of the 
national programs.
Measures of school performance
Primary outcomes of school performance included eligibility for USS and the grade point 
sum. Eligibility to USS was indicated by eligibility to a vocational program (i.e., the lowest 
requirement) and was determined using FGs as outlined above. The grade point sum is 
available in the NSR. For comparison with previous research, we calculated a GPA for each 
student by dividing the grade point sum by the number of graded subjects (range 0.0-20.0). 
The grade point sum can complement a GPA as its sensitivity to the number graded subjects 
differ. For instance, a treatment may increase subject enrollment while leaving the 
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performance in these subjects unaffected. A measure of teacher assessed school performance 
(subsequently referred to as teacher assessment) was created by first converting the 
alphabetical grades as outlined in Figure 1, and subsequently subtracting grade points in 
weighted tests from the corresponding FG in each of the core subjects (range −20.0-20.0). 
Since the standardized tests can be considered as a more objective measurement of academic 
knowledge, this difference can be expected to be more sensitive to behavioral aspects of 
school performance. As performance in compulsory school determines the options to 
advance to USS, completion of USS was included in the sensitivity analyses to test whether 
associations between ADHD, ADHD medication, and performance in compulsory school 
replicated for USS completion, which was ascertained using LISA and available for students 
graduating 2008-2010.
Medication for ADHD
We first calculated the number of days of medication usage covered by each dispensation 
based on the defined daily doses dispensed and the accompanying dosage instruction when 
available. The extent of treatment was then calculated in months for each individual from the 
start of grade 7 until graduation (Figure 1) or test while ignoring treatment status during the 
summer holiday (June 1 to August 15), leading to a treatment range of 0 to 29 months. 
Details on this procedure are found in online Supplement 1, Figure S1, and Table S1.
Covariates
Information about individual background factors (sex, immigration background, and month 
of birth) were obtained from the Total Population Register (TPR). Information about 
comorbid diagnoses of developmental disorder (ICD10: F80-F89) and behavioral disorders 
(ICD10: F91-98) disorder were obtained from the NPR. Parents were identified through the 
Multi Generation Register, linked to the TPR for information on immigration status, and 
linked to LISA for information on disposable income and highest educational attainment in 
the year of graduation. Parental educational attainment was divided into 4 levels: at most one 
parent USS, both parents USS, at least one parent with a (3 years or less) university 
education or at least one parent with 4 years of university education or more. Income was 
divided into quartiles calculated over the average sum of parental income between the year 
of the child’s graduation from year 9 and the two preceding years to account for year-to-year 
fluctuations. When information on parental income and education was missing, information 
from the year closest to the child’s graduation was used if available.
Analyses
The association between ADHD and school performance—To explore school 
performance in adolescents with ADHD compared to adolescents without ADHD we used 
two types of regression models. Logistic regression models were used for the binary 
outcome eligibility for USS. When school performance was a continuous measure (i.e., the 
grade point sum, GPA, and teacher assessments) we used linear regression models. To 
disseminate the influence of potential confounding factors, each association was estimated 
with and without adjustments for covariates. Individual level covariates included were month 
of birth (continuous, range 1-12), sex, year of graduation (6 categories), years resident in 
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Sweden (range 0.0-16.0), age at graduation (<15.5, 15.5 to 16.5, >16.5), indicators (1 when 
present, 0 otherwise) of diagnosis of developmental and behavioral disorders respectively. 
Parental background factors included immigration status (no, one, or both parents born 
abroad), combined educational level, and income quartile. The adjusted model was 
estimated within school of graduation (i.e. a fixed-effects approach) using robust standard 
errors clustered on this unit.
The association between ADHD medications and school performance—We 
estimated the association between medication and school performance by extending the 
logistic (i.e., for binary outcomes) and linear (i.e., for continuous outcomes) regression 
models outlined above with treatment exposures. An indicator of ever being treated between 
the start of grade 7 and test or graduation was used to account for baseline differences 
between the treated and untreated groups in terms of the outcome. Months on ADHD 
medication (range 0.0-29.0) prior to test or graduation was entered as a continuous covariate. 
To account for non-linear effects, a quadratic term of months on ADHD medication was 
included in the models. When the quadratic term was statistically significant (p<0.05) the 
combined association was reported. Since estimates including non-linear effects differ 
according to treatment length, the estimates were scaled to 3 and 29 months to reflect 
treatment periods of 3 months and the entire three school years preceding graduation 
respectively. The relationship between the grade point sum and ADHD medication was also 
plotted against treatment length including estimates stratified by treatment length to assess 
the fit of the association.
Risk differences (RDs) and standardized coefficients (SCs)—To aid the 
interpretation of estimates in the logistic models, RDs were calculated for point estimates. 
The RD is the average difference in the probability of the outcome due to a unit change in 
the exposure (i.e., ADHD status or treatment length) predicted from the fitted model given 
the underlying covariate data.27 For continuous outcomes, SCs were calculated by 
multiplying the point estimate with the standard deviation of the exposure and dividing with 
the standard deviation of the outcome. A standard deviation increase in the exposure thus 
increases the outcome with a standardized coefficient (SC) standard deviations. Point 
estimates of RDs and SCs were provided for estimates mentioned in text, and for all 
outcomes in supplementary tables.
Sensitivity analyses—The sensitivity analyses focused on the association between 
ADHD medication and school performance. First, different treatment groups were defined 
according to the pattern of dispensations and stratifying the analyses on these groups. 
Similar to previous research17, continuous treatment was defined as a treatment extent 
covering the remaining 70 percent of the scholastic months following the student’s first 
observed dispensation of ADHD medication up until the time of the outcome (test or 
graduation). Discontinuous treatment was defined as a treatment pattern not classifiable as 
continuous. Further details on the definition of these treatment groups are found in online 
Supplement 2, Figure S2, and Table S2. Second, we performed analyses excluding cases that 
did not carry a clinical diagnosis of ADHD, and third, excluding cases that were dispensed 
an ADHD medication prior to the 3-year period in which medication use was calculated. 
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Fourth, we used logistic regression models to investigate whether treatment length at 
graduation was predictive of not completing USS within 3 years among students graduating 
2008-2010.
Analyses were conducted using R version 3.4.4 (R core team, Vienna, Austria), package 
drgee28 for continuous outcomes and package bife27 for binary. Routines in bife were also 
used to calculate RDs.
RESULTS
Descriptives
Of the 657,720 students graduating in 2008 to 2013, 29,128 (4.4%) students had either 
received a diagnosis of ADHD and/or dispensation of ADHD medication. There were fewer 
females in the ADHD group (35.8%), than in the student population without ADHD 
(49.4%). A larger portion of students with ADHD (12.5%) graduated later than expected 
based on their age, compared to students without ADHD (3.8%). A comorbid diagnosis of 
developmental disorder was found in 14.9% of the ADHD group compared to 1.2% in the 
unaffected group and for behavioral disorders 15.5% in the ADHD group compared to 1.9% 
in the unaffected group. Parents of students with ADHD had fewer years of education and 
were about 6 percentiles lower in the income distribution than parents of students without 
ADHD. The share of females was lower in the group treated with ADHD medications prior 
to graduation (27.9%) than the ADHD group in general. Otherwise the differences in the 
ADHD group by treatment status were negligible (Table 1).
The association between ADHD and school performance
Students with ADHD were at increased risk of not being eligible to USS, 37.6% compared 
to 10.7% in the student population unaffected by ADHD; adjusted odds ratio (AOR) 4.70 
(95% confidence interval [CI]: 4.56; 4.85); RD=19.9%. The ADHD group received a lower 
grade point sum (max=320), 136.8 compared to 211.0 points among students unaffected by 
ADHD; adjusted grade point difference (βA) −56.40 (−57.47; −55.33); SC=−0.17. ADHD 
was negatively associated with teacher assessments (i.e., FG minus test) in Swedish and 
English, but displayed a positive association in mathematics (Table 2). ADHD associated 
with significantly lower grade points (βA) in tests and FGs of core subjects (Swedish, 
English, and mathematics), and other subjects, ranging from −2.32 to −3.99 grade points 
(see Table S3, available online).
The association between ADHD medication and school performance
One treatment period (i.e., three months) significantly decreased the odds of not being 
eligible to USS, AOR=0.80 (0.76; 0.84), RD=−1.9%, and was associated with a higher grade 
point sum of βA=9.35 (7.88; 10.82) points, SC=0.20. Positive associations were observed 
between ADHD medication and teacher assessments (i.e., FG minus test) in all core subjects 
(Table 3). Statistically significant, positive associations between ADHD medication and FGs 
(βA range 0.09 to 0.58) were observed for all subjects while the only significant association 
with tests was found for mathematics and Swedish (see Table S4, available online).
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Scaling the adjusted estimates to the maximum treatment length (29 months) amounted to a 
lower likelihood of not being eligible for USS of AOR=0.50 (0.39; 0.63), RD=−6.0%, and a 
grade point sum βA=40.84 (34.49; 47.18) points higher (Table 3). Figure 2 illustrates the 
association between treatment length and the grade point sum, including the modeled trend, 
absolute and relative (adjusted) grade points stratified by treatment length. The model 
displays a close dose-response relationship with the relative grade points when extrapolating 
the estimated association beyond the 3-month treatment period and indicates that the effect 
of medication is diminishing over treatment length. This means that according to the model, 
the estimated difference in grade sum between, for instance, 18 and 21 months of treatment 
is smaller than the corresponding difference between 3 and 6 months.
Sensitivity analyses
Stratifying the analyses by treatment group (continuous or discontinuous) did not reveal any 
systematic differences between the groups in terms of school performance (see Table S5, 
available online). The associations also remained robust to the exclusion of ADHD cases 
without a clinical diagnosis of ADHD, and cases with a dispensed medication prior to the 
period over which medication use was calculated (see Table S6–7, available online). 
Treatment length prior to graduation from compulsory school was predictive of completing 
USS within 3 years where one treatment period was significantly associated with a reduction 
in the odds of not completing USS, AOR=0.89 (0.87; 0.91); RD=−1.8% (Table 3).
DISCUSSION
To our knowledge, this is the largest study to examine the associations among ADHD, 
medication usage, and school performance. We used a population cohort of 657,720 
individuals graduating from compulsory school between 2008 and 2013. The main findings 
were that ADHD has a substantial negative impact on school performance that is 
independent of several important confounders (e.g., parental education), and that 
pharmacological treatment for ADHD is associated with an attenuation in this relationship. 
For instance, we estimated the ADHD associated risk of ineligibility for USS to 19.9 percent 
and the modeled risk reduction associated with the longest treatment length to −6.0 percent 
yielding a residual risk of 13.9 percent. Our findings thus highlight the need to detect ADHD 
at an early stage, and that other non-pharmacological educational interventions are likely 
needed if school performance in students with ADHD is to be normalized. From an 
educational policy perspective, it can be proposed that pharmacological treatment should at 
most be viewed as an aid to facilitate learning, and without the proper educational support 
for the affected students it appears unlikely that such treatment would translate into large 
gains in knowledge.
Our finding that pharmacological treatment for ADHD is positively associated with several 
measures of school performance is consistent with previous observational studies.17,21,22 
The largest previous study (NADHD=3543) reported an improvement in GPA of 0.11 points 
during stimulant adherent marking periods (≈78 days).17 Expressing this effect as a 
percentage of maximum GPA (4.0) would yield an effect size of 2.7%. The corresponding 
effect size in our study was 2.1% which indicates a weaker relationship between ADHD 
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medication and school performance, possibly due to differences in source population 
(Medicaid claims versus national registers), study question (treatment adherence versus 
length), and school system as students in Sweden are generally not separated based on 
abilities (with some exceptions). Other available studies are less comparable due to 
differences in design, outcome measures, or substantially longer follow-ups than the three 
years used in our study. Of these, a small study (NADHD=90) where participants had an 
average treatment duration of 5.33 years found that medicated individuals had a 0.6 point 
higher GPA (max=4.0) compared to unmedicated individuals.21 Concerning standardized 
tests, one of the larger studies (NADHD=594) found that ADHD medication was associated 
with a 2.9 point higher score in mathematics and 5.4 in reading.22 Other studies have found 
significant positive correlations in this domain, but do not report effect sizes.19,20,29 Our 
findings are inconsistent with two follow-ups of the MTA-study reporting no statistically 
significant association between past year ADHD medication use and GPA20, and between 8-
year medication use and test scores in mathematics.19 The differences could be due to 
several factors. First, it is unclear whether these studies addressed confounding by indication 
appropriately (i.e., whether ADHD medication was indicative of lower school performance). 
This is problematic as our results illustrate (Figure 2) that students receiving ADHD 
medication prior to graduation are performing worse in terms of school performance 
compared to students treated later or not at all. Thus, not accounting for the baseline 
differences between treatment groups may bias the estimated effect of ADHD medication on 
school performance. Second, our results indicate that improvements in school performance 
diminish with increasing treatment length. It is possible that the additional gains at the 8-
year follow-up are too small to detect given the sample size in the MTA-study and the low 
frequency of treatment naïve individuals.
Our study extends previous research on ADHD, the effect of ADHD medication, and school 
performance in several ways. First, by estimating how the usage of ADHD medication over 
several years affects school performance we show how short-term effects potentially 
translate to long-term effects.
Second, by including a measure of teacher assessment (the grade point difference between 
FGs and tests) we were able to include a more comprehensive set of school performance 
measures and thereby explore new aspects of how ADHD, and ADHD medication, is 
associated with school performance. We found that, after accounting for their test 
performance, students with ADHD receive a lower FG in Swedish and English, but a higher 
FG in mathematics, compared to students without ADHD. Consistent with previous 
research,18,19 these findings suggest that teacher assessment differs by ADHD status. 
Furthermore, research using Swedish data has revealed that differences between tests and 
FGs are systematically related to student background characteristics such as sex and 
socioeconomic status.30 Possible explanations for the negative differences (Swedish and 
English), and positive difference in mathematics, are that the behavioral aspects associated 
with ADHD, such as classroom productivity and disturbance, are taken into account by 
teachers as the classroom environment likely differs between languages and mathematics. If, 
and to what extent, this type of grading behavior exists in other educational systems is an 
important direction for future research on ADHD and school performance to take.
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Third, the positive associations between ADHD medication and teacher assessments coupled 
with the absent, or small relative to FGs, associations with tests (see Table S4, available 
online), suggest that the main treatment related improvements are not in terms of subject 
knowledge as measured by standardized tests. As Swedish and English are subjects that 
place more focus language related skills (e.g., reading, writing) than mathematics, 
potentially medication affects these subjects differentially via their respective skill 
requirements. Such an interpretation is supported by a recent meta-analysis of the effect of 
methylphenidate on academic performance reporting positive effects on mathematics 
productivity and accuracy, but only productivity for reading.31 This highlights the 
importance in considering the domain (e.g., academic knowledge, classroom behavior and 
productivity) of school performance when assessing the potential benefits of ADHD 
medication.
The current study has limitations that need to be highlighted. It is not possible to determine 
whether students received concurrent non-pharmacological treatment or supportive measures 
such as teaching in a smaller group setting, help by extra personnel, or if the school 
specialized in teaching students with ADHD, as this information is not available in the 
registers. According to a report from 2016, about 5 percent of 7th graders and 8 percent of 
9th graders in Sweden receive some form of educational support in compulsory school.32 
The presence of such supportive resources is not necessarily problematic since these 
interventions are likely to cluster at the school level and are thus accounted for in our 
analyses. However, if treatment is increasing in schools in which such resources are 
provided over time, or other unmeasured factors correlated with treatment length are present, 
our estimates might be positively biased. We do find that the strongest predictor of treatment 
assignment and length by far is year of graduation, reflecting an increase over time in the 
utilization of ADHD medication, but that other measured background factors at the 
individual and parental level are of relatively low importance neither for the extent of 
treatment nor for initiating treatment earlier or individual treatment pattern (see Table S8, 
available online). Nonetheless, despite controlling for an important set of confounders, it 
must be emphasized that the non-randomized design with regards to pharmacological 
treatment initiation is an inherent limitation of our results that precludes a causal 
interpretation.
ADHD is associated with substantially lower school performance. Pharmacological 
treatment of ADHD is associated with higher grades, eligibility for, and completion of, USS. 
The strength of these associations suggest that interventions targeting school performance 
should be initiated early, in conjunction with medication when considered appropriate by 
clinicians and the relevant stakeholders, for closing the school performance gap associated 
with ADHD. Potential beneficial effects of medication on school performance should be 
carefully weighed against potential adverse effects of medication, including side-effects 
(e.g., disturbed sleep, appetite loss), and problems with misuse and diversion.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Students with ADHD are at risk for poor school performance.
• Duration of medication use is associated with higher levels of school 
performance.
• Parents and teachers should be encouraged to monitor school performance in 
students with ADHD and address difficulties at an early stage.
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Measurement of Medication Use, Grade Conversion, and Outcome Measures in the Swedish 
School System from Compulsory to Upper Secondary School
Note: Medication use measured during year 7-9 (shaded circles).
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Grade Point Sum by Length of Treatment with Attention-Deficit/Hyperactivity Disorder 
(ADHD) Medication
Note: See Table 3 for details of the statistical model. Months in treatment (prior to 
graduation from compulsory school) have been rounded upwards.
Left scale: Crosses represent the means. (a) Students with ADHD not treated prior to 
graduation.
Right scale: Dots represent the adjusted grade point sum by treatment length relative to 
students with ADHD not treated prior to graduation. The black line represents the modelled 
change in grade point sum extrapolated over treatment length. (b) The adjusted grade point 
sum of students with ADHD not treated prior to graduation relative to those treated prior to 
graduation
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TABLE 1.
Demographic Characteristics of the Student Population Graduating Swedish Compulsory School 2008-2013 
by Attention-Deficit/Hyperactivity Disorder (ADHD) and Treatment Status
Non-ADHD ADHD Treated prior to graduation
Total 628,592 (95.6) 29,128 (4.4) 16,054 (55.1)
Individual background
Female 310,592 (49.4) 10,435 (35.8) 4,485 (27.9)
Age at graduation
Less than 15.5 50,610 (8.1) 1,925 (6.6) 992 (6.2)
15.5 to 16.5 553,941 (88.1) 23,562 (80.9) 12,701 (79.1)
Greater than 16.5 24,041 (3.8) 3,641 (12.5) 2,362 (14.7)
Birth month
a 6.2 (3.4) 6.6 (3.4) 6.6 (3.4)
Immigrant 52,576 (8.4) 1,469 (5.0) 821 (5.1)
Years resident in Sweden 15.3 (2.7) 15.8 (1.4) 15.8 (1.4)
Comorbidity
Behavioral disorder 12,040 (1.9) 4,502 (15.5) 2,699 (16.8)
Developmental disorder 7,387 (1.2) 4,332 (14.9) 2,607 (16.3)
Family background
Immigrant 135,049 (21.7) 4,471 (15.7) 2,259 (14.4)
One parent born abroad 56,248 (9.0) 2,759 (9.7) 1,465 (9.3)
Both parents born abroad 78,801 (12.7) 1,712 (6.0) 794 (5.1)
Parental income percentile
a 50.8 (28.9) 45.0 (27.7) 45.3 (27.5)
Missing 6,619 (1.1) 633 (2.2) 388 (2.4)
Parental education
One parent secondary education 128,695 (20.7) 8,146 (28.6) 4,567 (29.2)
Both parents secondary education 180,397 (29.1) 9,477 (33.3) 5,392 (34.5)
At least one parent tertiary education 217,555 (35.1) 8,087 (28.4) 4,266 (27.3)
At least one parent 4 years of tertiary education or more 93,636 (15.1) 2,758 (9.7) 1,423 (9.1)
Missing 8,309 (1.3) 660 (2.3) 406 (2.5)
Note: N (%) unless specified.
a
Mean (standard deviation)
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TABLE 2.
The Association Between Attention-Deficit/Hyperactivity Disorder (ADHD) and School Performance in the 
Student Population Graduating Swedish Compulsory School
ADHD status Estimated association with ADHD
ADHD Non-ADHD Unadjusted Adjusted
Outcome N (%) OR (95% CI)
Not eligible to USS 10,954 (37.6) 67,505 (10.7) 5.01*** (4.89; 5.14) 4.70*** (4.56; 4.85)
Not completed USS 9,583 (67.8) 74,296 (21.9) 7.50*** (7.23; 7.78) 5.84*** (5.61; 6.08)
M (SD) Grade point β (95% CI)
Grade point average 9.0 (4.1) 13.3 (3.8) −4.30*** (−4.35; −4.25) −3.29*** (−3.35; −3.23)
Grade point sum 136.8 (71.8) 211.0 (64.7) −74.21*** (−75.05; −73.37) −56.40*** (−57.47; −55.33)
Teacher assessment
Swedish 0.3 (3.4) 0.7 (2.7) −0.45*** (−0.50; −0.41) −0.35*** (−0.40; −0.31)
English −0.3 (2.6) 0.1 (2.2) −0.33*** (−0.36; −0.29) −0.25*** (−0.29; −0.21)
Mathematics 1.9 (4.0) 1.6 (3.4) 0.24*** (0.18; 0.29) 0.23*** (0.17; 0.29)
Note: The sample includes all students that graduated compulsory school 2008-2013 unless specified. ADHD status determined by lifetime in-/
outpatient diagnosis of ADHD or dispensation of ADHD medication. The adjusted model is estimated within the school unit and standard errors 
have been clustered on this unit. Covariate adjustments include sex (2 levels), year of graduation (6 levels), parental education (4 levels) and income 
quartile at graduation (4 levels), parents born abroad (none, one or two), years resident in Sweden (0.0-16.0), month of birth (1-12) ), age at 
graduation (<15.5, 15.5 to 16.5, >16.5), indicators of comorbid developmental and behavioral disorder.
USS: Upper secondary school.
Not eligible to USS: Indicator of being eligible to USS requiring passing Swedish, English, Mathematics for graduates 2008-2010, and for 
graduates 2011-2013 passing an additional 5 subjects for a vocational program.
Not completed USS: Indicator of having completed USS within 3 years of graduation within the student population graduating compulsory school 
2008-2010.
Grade point sum: The sum of grade points in leaving certificates of the student’s 16 best performing subjects.
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